Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 24
1991 73
1992 138
1993 227
1994 228
1995 311
1996 338
1997 348
1998 375
1999 383
2000 404
2001 437
2002 507
2003 460
2004 427
2005 438
2006 399
2007 372
2008 370
2009 383
2010 394
2011 444
2012 435
2013 429
2014 418
2015 410
2016 315
2017 309
2018 318
2019 333
2020 312
2021 344
2022 295
2023 273
2024 267
2025 265
2026 68

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,299 results

Results by year

Filters applied: . Clear all
Page 1
Clinical pharmacokinetics of losartan.
Sica DA, Gehr TW, Ghosh S. Sica DA, et al. Clin Pharmacokinet. 2005;44(8):797-814. doi: 10.2165/00003088-200544080-00003. Clin Pharmacokinet. 2005. PMID: 16029066 Review.
Losartan is the first orally available angiotensin-receptor antagonist without agonist properties. ...Losartan, or its E 3174 metabolite, is not removed during haemodialysis. The major metabolic pathway for losartan is by the cytochrome P450 (CYP) 3A4, 2C9 an …
Losartan is the first orally available angiotensin-receptor antagonist without agonist properties. ...Losartan, or its E 3174 …
Topical Losartan in the Management of Corneal Scarring Fibrosis: Update on Dosage, Efficacy, and Potential Epithelial Toxicity.
Dutra BAL, Wilson SE. Dutra BAL, et al. J Ocul Pharmacol Ther. 2025 Jun;41(5):232-236. doi: 10.1089/jop.2024.0200. Epub 2025 Apr 16. J Ocul Pharmacol Ther. 2025. PMID: 40238717 Review.
Several human case reports have subsequently shown the efficacy of topical losartan in treating scarring fibrosis resulting from surgical complications and infections. Since rabbit studies have also found concentration-dependent corneal epithelial toxicity associated with …
Several human case reports have subsequently shown the efficacy of topical losartan in treating scarring fibrosis resulting from surg …
Losartan: Comprehensive Profile.
Al-Majed AR, Assiri E, Khalil NY, Abdel-Aziz HA. Al-Majed AR, et al. Profiles Drug Subst Excip Relat Methodol. 2015;40:159-94. doi: 10.1016/bs.podrm.2015.02.003. Epub 2015 Apr 9. Profiles Drug Subst Excip Relat Methodol. 2015. PMID: 26051686 Review.
Losartan (Cozaar ) is an angiotensin II receptor antagonist with antihypertensive activity. ...Physical characteristics including: ionization constant, solubility, X-ray powder diffraction pattern, thermal methods of analysis, UV spectrum, IR spectrum, mass spectrum with f …
Losartan (Cozaar ) is an angiotensin II receptor antagonist with antihypertensive activity. ...Physical characteristics including: io …
[Losartan].
Quetglas EG, Sádaba B, Escolar M, Honorato J. Quetglas EG, et al. Rev Med Univ Navarra. 1997 Jul-Sep;41(3):193-7. Rev Med Univ Navarra. 1997. PMID: 10420926 Review. Spanish. No abstract available.
Losartan ameliorates renal interstitial fibrosis through metabolic pathway and Smurfs-TGF-beta/Smad.
Zou J, Zhou X, Ma Y, Yu R. Zou J, et al. Biomed Pharmacother. 2022 May;149:112931. doi: 10.1016/j.biopha.2022.112931. Epub 2022 Apr 7. Biomed Pharmacother. 2022. PMID: 36068784 Free article.
In this study, we investigated the effects of losartan on Unilateral Ureteral Obstruction (UUO) model mice by studying the changes in the TGF-beta/Smad and metabolomics. Male C57BL/6 J mice were intervened with the UUO model and given losartan (10, 20, 30 mg/kg/d) f …
In this study, we investigated the effects of losartan on Unilateral Ureteral Obstruction (UUO) model mice by studying the changes in …
Topical Losartan in the Treatment of Stromal Scarring After Refractive Surgery.
Wilson SE, Dutra BAL, Wahabi K. Wilson SE, et al. J Refract Surg. 2025 Jun;41(6):e602-e610. doi: 10.3928/1081597X-20250506-05. Epub 2025 Jun 1. J Refract Surg. 2025. PMID: 40488485 Review.
Cases with bilateral late haze after PRK are less likely to respond to topical losartan due to the underlying defect that originally led to the development of fibrosis affecting the losartan two-phase mechanism of action. CONCLUSIONS: Topical losartan has an …
Cases with bilateral late haze after PRK are less likely to respond to topical losartan due to the underlying defect that originally …
Pharmacokinetic evaluation of losartan.
Burnier M, Wuerzner G. Burnier M, et al. Expert Opin Drug Metab Toxicol. 2011 May;7(5):643-9. doi: 10.1517/17425255.2011.570333. Epub 2011 Mar 22. Expert Opin Drug Metab Toxicol. 2011. PMID: 21417956 Review.
As the first angiotensin II receptor blocker (ARB) on the market, losartan belongs to the most frequently prescribed ARB. AREA COVERED: The present review examines the pharmacokinetics of losartan with a special discussion on the dose of losartan that should …
As the first angiotensin II receptor blocker (ARB) on the market, losartan belongs to the most frequently prescribed ARB. AREA COVERE …
Effects of Losartan and Fisetin on Microfracture-Mediated Cartilage Repair of Ankle Cartilage in a Rabbit Model.
Stake IK, Gao X, Huard M, Fukase N, Ruzbarsky JJ, Ravuri S, Layne JE, Philippon MJ, Clanton TO, Huard J. Stake IK, et al. Am J Sports Med. 2024 Dec;52(14):3625-3640. doi: 10.1177/03635465241285902. Epub 2024 Nov 3. Am J Sports Med. 2024. PMID: 39491502
METHODS: Four-month-old female rabbits were divided into the following groups (8 rabbits per group): microfracture only (microfracture), microfracture plus losartan (losartan), microfracture plus fisetin (fisetin), and microfracture plus losartan and fisetin …
METHODS: Four-month-old female rabbits were divided into the following groups (8 rabbits per group): microfracture only (microfracture), mic …
Losartan in diabetic nephropathy.
Carswell CI, Goa KL. Carswell CI, et al. Drugs. 2003;63(4):407-14; discussion 415-6. doi: 10.2165/00003495-200363040-00006. Drugs. 2003. PMID: 12558462 Review.
Losartan is an orally active, selective, nonpeptide, angiotensin II AT(1) receptor antagonist. ...In addition, data from several nonblind and double-blind studies indicates that losartan effectively reduces the mean albumin excretion rate. Two double-blind studies s …
Losartan is an orally active, selective, nonpeptide, angiotensin II AT(1) receptor antagonist. ...In addition, data from several nonb …
Losartan-induced hepatic injury.
Tabak F, Mert A, Ozaras R, Biyikli M, Ozturk R, Ozbay G, Senturk H, Aktuglu Y. Tabak F, et al. J Clin Gastroenterol. 2002 May-Jun;34(5):585-6. doi: 10.1097/00004836-200205000-00022. J Clin Gastroenterol. 2002. PMID: 11960076 Review.
Losartan, an angiotensin II receptor antagonist, is widely used for the treatment of hypertension. Clinical experience with this drug has demonstrated that it is safe. Losartan-induced hepatic toxicity is extremely rare. We report a case of severe hepatic toxicity a …
Losartan, an angiotensin II receptor antagonist, is widely used for the treatment of hypertension. Clinical experience with this drug …
11,299 results
You have reached the last available page of results. Please see the User Guide for more information.